Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2022-04-27 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物第一届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Hangzhou Anxu Biotechnology Co., Ltd. It discusses the review and approval of various reports including the 2021 Annual Report, 2022 Q1 Report, profit distribution plan, audit firm reappointment, and other related proposals. The document repeatedly states that these reports and proposals will be submitted to the 2021 Annual General Meeting for approval and references that the full reports are disclosed separately on the Shanghai Stock Exchange website. The document itself does not contain the full annual or quarterly reports but rather the Supervisory Board's resolutions and opinions on them. It is a formal announcement of meeting resolutions and approvals rather than the reports themselves. Therefore, it fits best into the category of Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice, not the actual Annual Report (10-K) or Interim Report (IR).
2022-04-27 Chinese
民生证券股份有限公司关于杭州安旭生物科技股份有限公司2021年度募集资金存放与使用情况的专项核查意见
Regulatory Filings
2022-04-27 Chinese
安旭生物关于未披露内部控制评价报告的说明
Regulatory Filings Classification · 95% confidence The document is a statement from Hangzhou Anxu Biotech Co., Ltd. explaining the non-disclosure of the 2021 internal control evaluation report. It references regulatory guidelines from the China Securities Regulatory Commission and explains that as a newly listed company in 2021, it is exempt from disclosing the internal control evaluation report for that year, with plans to disclose it alongside the next annual report. The document is short (1129 characters) and serves as an explanatory announcement rather than the report itself. It does not contain financial statements or substantive financial data. Therefore, it fits the category of a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2022-04-27 Chinese
安旭生物2021年年度报告
Annual Report Classification · 100% confidence The document is titled "2021 年年度报告" which translates to "2021 Annual Report." It contains detailed financial data, management discussion and analysis, company overview, financial statements, and audit opinions. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes sections such as management discussion and analysis, financial data, audit report, and corporate governance, which are typical components of an Annual Report (10-K equivalent). There is no indication that this is merely an announcement or a certification document. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-04-27 Chinese
安旭生物2021年年度报告摘要
Annual Report Classification · 100% confidence The document is titled '2021 年年度报告摘要' which translates to '2021 Annual Report Summary'. It contains detailed financial data for the year 2021, including total assets, net profit, revenue, and quarterly breakdowns. It also includes company business descriptions, industry analysis, shareholder information, and risk disclosures. The document is over 11,000 characters, indicating it is a substantive report rather than a brief announcement. The content aligns with the characteristics of an Annual Report (10-K) as it covers comprehensive company activity and full financial performance for the fiscal year 2021. There is no indication that this is merely an announcement or a certification, and it is not a quarterly or interim report. Therefore, the correct classification is Annual Report (10-K). FY 2021
2022-04-27 Chinese
安旭生物关于增加远期结售汇及外汇衍生产品业务额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Hangzhou Anxu Biotech Co., Ltd. regarding the increase in the business limit for forward foreign exchange settlement and foreign exchange derivative products. It details the board and supervisory meetings approving the increase, the purpose of the foreign exchange business, risk analysis, and risk control measures. The document is a formal announcement of a corporate decision related to financing and risk management activities involving foreign exchange derivatives. It does not contain financial statements or detailed financial performance data, nor is it a transcript, report, or voting result. The content fits best under Capital/Financing Update (CAP) as it relates to updates on the company's foreign exchange business limits and related financial risk management activities.
2022-04-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.